Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 ...

Scholar Rock's experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early ...

Discover six innovative clinical-stage biotech companies fostering R&D in the Duchenne muscular dystrophy therapeutic space.

Our Bureau, Mumbai Friday, September 27, 2024, 16:15 Hrs [IST] ...

SIADH (syndrome of inappropriate antidiuretic hormone secretion) leads to hyponatremia water retention in hospitalized or ...

SIADH (syndrome of inappropriate antidiuretic hormone secretion) leads to hyponatremia water retention in hospitalized or ...

Looking for help burning fat and curbing your appetite? We compared the best weight loss supplements, analyzing their ...